Key result
Angiotensin II receptor blockers decrease heart failure hospitalizations, but no studies have demonstrated a convincing decrease in mortality.
Why the study?
Do Angiotensin II receptor blockers (ARBs) reduce mortality and heart failure hospitalization in heart failure patients?
Do Angiotensin II receptor blockers (ARBs) reduce mortality and heart failure hospitalization in heart failure patients?
Answers are grounded in this paper and cite their sources.
ARBs are effective and well-tolerated in heart failure, reducing hospitalizations, but have not yet shown a convincing mortality benefit.
Evidence from large, randomized, controlled clinical trials supports the use of angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and spironolactone to reduce mortality and morbidity. Despite these effective therapies, event rates related to heart failure remain high. Although ACE inhibitors reduce angiotensin II production, they do not fully suppress the increased angiotensin II production in heart failure. Angiotensin II receptor blockers (ARBs) directly block the effect of angiotensin II, derived from any source, at the receptor level and have the potential to be as effective or even more effective than ACE inhibitors. The results of a number of clinical studies have demonstrated ARBs are effective and well tolerated. However, no studies have demonstrated a convincing decrease in mortality with ARB use, although a decrease has been observed for heart failure hospitalization. The results from further studies are awaited to clarify the role of ARBs in the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Theal et al. (2003) conducted a review in Heart failure. Angiotensin II Receptor Blockers (ARBs) was evaluated. Angiotensin II receptor blockers decrease heart failure hospitalizations, but no studies have demonstrated a convincing decrease in mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: